Date: Sunday, November 8, 2020
Session Title: Reproductive Issues in Rheumatic Disorders (1497–1501)
Session Type: Abstract Session
Session Time: 3:00PM-3:50PM
Background/Purpose: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine (HCQ) was initially considered as a prophylaxis and treatment of COVID-19. Despite this optimism, more extensive reports have significantly dampened the promise of efficacy, however cardiac toxicity has surfaced raising attention to this complication. Although HCQ is generally considered safe during pregnancy based on studies in patients with systemic lupus erythematous and other rheumatic conditions, this initiative leveraged a unique opportunity to evaluate neonatal electrocardiograms (ECGs) in the context of HCQ levels to address any potential cardiotoxicity.
Methods: Neonatal ECGs and HCQ blood levels were available in a recently completed study evaluating the efficacy of HCQ 400mg daily to prevent the recurrence of congenital heart block associated with anti-SSA/Ro antibodies. The ECGs of affected newborns who met the primary outcome of advanced block were not included in this safety study so that the results only reflect those infants with no clinical cardiac disease. Using the Bazett formula to correct for heart rate, corrected QT (QTc) intervals were calculated and compared to age-matched normal values. For reference, the median (2nd percentile – 98th percentile) values for QTc were 413 (378-448) msec in males, and 420 (379-462) msec in females. QTc intervals were recorded in the absence of knowledge of the HCQ levels. Values exceeding 448 msec for males and 462 msec for females were considered abnormal. Levels of HCQ were assessed during each trimester of pregnancy and in the cord blood, providing unambiguous assurance of drug exposure.
Results: There were 45 ECGs available for interpretation within the first 4 months of life in unaffected infants. Overall, there was no correlation between cord blood levels of HCQ and the QTc (R = 0.02, P = 0.86) or the average value of HCQ levels obtained during each individual pregnancy and cord blood and the QTc (R = 0.04, P = 0.80), as shown in Figure 1A and Figure 1B. Likewise there was no correlation between the average of the maternal HCQ levels obtained at each trimester and delivery plus cord levels and the QTc on the ECGs of the 31 infants evaluated on day of life 1-4 (R = 0.08, P = 0.63) or those of the 14 children older than 4 days (R = 0.01, P = 0.95). Maternal values of HCQ were sustained throughout pregnancy and delivery (Figure 2). Mean QTc values were nearly identical between those in the highest and lowest quartiles of cord blood HCQ levels (P = 0.57) and between the highest and lowest quartiles of average HCQ levels during pregnancy (P = 0.54) (Figure 3A and 3B). Among these 45 infants, only 5 had prolongation of the QTc (11%; 95% CI: 4% – 24%), 2 marked and 3 marginal. No arrhythmias occurred in any neonate that was not known to have heart block.
Conclusion: In aggregate, these data provide reassurances that the maternal use of HCQ is not associated with a high incidence of QTc prolongation in the neonate.
Figure 1. Correlation between blood HCQ levels and neonatal QTc. (Panel A) Cord HCQ is plotted against QTc. (Panel B) Overall mean HCQ levels (obtained by averaging all HCQ levels throughout an individual pregnancy and cord blood level) are plotted against QTc. Subjects with an abnormally prolonged QTc are designated with red bold circles. All QTc intervals were calculated using the Bazett formula (QTcB).
Figure 2. Box plots of maternal blood levels of HCQ during each trimester of pregnancy and delivery. M1T is baseline first trimester. M2T is second trimester. M3T is third trimester. M-Delivery is at the time of delivery. Median levels of HCQ (interquartile range) for M1T: 669 ng/mL (363-941); M2T: 877 ng/mL (604-1212); M3T: 849 ng/mL (652-1000); M-Delivery: 815 ng/mL (645-1080). Mean values denoted by + in box plot.
Figure 3. Box plots of QTc interval data for subjects in first and fourth quartiles of cord blood HCQ levels and average HCQ levels during pregnancy. (Panel A) Comparison of QTc between the first and fourth quartiles of HCQ cord blood levels. Median QTc (interquartile range) in first HCQ quartile: 417 msec (390- 424); in fourth HCQ quartile: 419 msec (404-436). (Panel B) Comparison of QTc between the first and fourth quartiles of HCQ levels averaged over pregnancy and cord blood. Median QTc (interquartile range) in first HCQ quartile: 413 msec (398, 443); in fourth HCQ quartile: 433 msec (407, 455). Mean values denoted by + in box plots. All QTc intervals were calculated using the Bazett formula (QTcB).
To cite this abstract in AMA style:Friedman D, Kim M, Costedoat-Chalumeau N, Clancy R, Copel J, Phoon C, Cuneo B, Cohen R, Masson M, Wainwright B, Zahr N, Saxena A, Izmirly P, Buyon J. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/electrocardiographic-qt-intervals-in-infants-exposed-to-hydroxychloroquine-throughout-gestation/. Accessed November 25, 2020.
« Back to ACR Convergence 2020
ACR Meeting Abstracts - https://acrabstracts.org/abstract/electrocardiographic-qt-intervals-in-infants-exposed-to-hydroxychloroquine-throughout-gestation/